ICAM-1

Home
Ligands
ICAM-1 (Human)

GtoPdb Ligand ID: 6757

Compound class: Endogenous peptide in human, mouse or rat

Comment: ICAM-1 is a cell-adhesion molecule that is overexpressed on the surface of a number of cancer cells types [1,5], and this may be correlated with metastasis and poor prognosis [3]. These findings suggest ICAM-1 as an ideal target for oncology therapeutic development [2]. Monoclonal antibodies (and antibody-drug conjugates) that target ICAM-1 are being explored for anti-tumour potential [4,6-7], and there is a report of the experimental effect of ICAM-1 targeting CAR-T cells in triple-negative breast cancer [8].

Species: Human

References
1. Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. (2014) ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A, 111 (41): 14710-5. [PMID:25267626]
2. Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA, Auguste DT. (2018) Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines. Nano Lett, 18 (4): 2254-2262. [PMID:29505261]
3. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, Li Y, Wang X, Zhang W, Wang Z et al.. (2017) Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression. Nat Commun, 8: 14035. [PMID:28102193]
4. Huang J, Agoston AT, Guo P, Moses MA. (2020) A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. Advanced Science, [Epub ahead of print]. DOI: 10.1002/advs.202002852
5. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. (1992) Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes. Cancer, 69 (5): 1165-73. [PMID:1739916]
6. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG et al.. (2020) Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Clin Cancer Res, 26 (22): 6028-6038. [PMID:32917735]
7. Wang M, Liu W, Zhang Y, Dang M, Zhang Y, Tao J, Chen K, Peng X, Teng Z. (2019) Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer. J Colloid Interface Sci, 538: 630-637. [PMID:30554096]
8. Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z, Li H, Zheng M, Zhang N, Long C et al.. (2020) Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer. Front Immunol, 11: 573823. DOI: 10.3389/fimmu.2020.573823 [PMID:33072116]

References

1. Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. (2014)
ICAM-1 as a molecular target for triple negative breast cancer.
Proc Natl Acad Sci U S A, 111 (41): 14710-5. [PMID:25267626]

2. Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA, Auguste DT. (2018)
Using Atomic Force Microscopy to Predict Tumor Specificity of ICAM1 Antibody-Directed Nanomedicines.
Nano Lett, 18 (4): 2254-2262. [PMID:29505261]

3. Huang C, Li N, Li Z, Chang A, Chen Y, Zhao T, Li Y, Wang X, Zhang W, Wang Z et al.. (2017)
Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression.
Nat Commun, 8: 14035. [PMID:28102193]

4. Huang J, Agoston AT, Guo P, Moses MA. (2020)
A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer.
Advanced Science, [Epub ahead of print]. DOI: 10.1002/advs.202002852

5. Pandolfi F, Trentin L, Boyle LA, Stamenkovic I, Byers HR, Colvin RB, Kurnick JT. (1992)
Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor-infiltrating lymphocytes.
Cancer, 69 (5): 1165-73. [PMID:1739916]

6. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG et al.. (2020)
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Clin Cancer Res, 26 (22): 6028-6038. [PMID:32917735]

7. Wang M, Liu W, Zhang Y, Dang M, Zhang Y, Tao J, Chen K, Peng X, Teng Z. (2019)
Intercellular adhesion molecule 1 antibody-mediated mesoporous drug delivery system for targeted treatment of triple-negative breast cancer.
J Colloid Interface Sci, 538: 630-637. [PMID:30554096]

8. Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z, Li H, Zheng M, Zhang N, Long C et al.. (2020)
Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Front Immunol, 11: 573823. DOI: 10.3389/fimmu.2020.573823 [PMID:33072116]